When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
TCON - Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
TRACON Pharmaceuticals Inc.
TRACON Pharmaceuticals ([[TCON]] +2.8%) has initiated dosing in Phase 2 ENVASARC trial, evaluating envafolimab for undifferentiated pleomorphic sarcoma or myxofibrosarcoma, type of cancer in soft tissue. Interim data is expected in mid-2021.Primary objective of this 160-subject trial is of objective response rate with duration of response a key secondary endpoint.Envafolimab (KN035), is a single-domain antibody against PD-L1.